Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder Who Have Had Inadequate Response to Generalized Anxiety Disorder Treatment
NCT06701903 is registered in ClinicalTrials.gov with Intra-Cellular Therapies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder Who Have Had Inadequate Response to Generalized Anxiety Disorder Treatment
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- November 21, 2024
- Completion date
- July 20, 2028
- Enrollment
- 570 (estimated)
- Sites
- 51
Conditions
As the registry lists them; a condition with its own page is linked.